Volume 11, Number 6—June 2005
Research
Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci in Rural Communities, Western United States
Kurt B. Stevenson*†
, Katy Searle†, Gregory Stoddard†, and Matthew H. Samore†‡
, Katy Searle†, Gregory Stoddard†, and Matthew H. Samore†‡
Table 5
Random effects Poisson regression model for HA-MRSA* rate†
| Predictors | No. of institutions | Incidence rate ratio | 95% CI | p value |
|---|---|---|---|---|
| Quintile of CA-MRSA rate‡ | ||||
| 1st–2nd: 0 | 11 | Reference | ||
| 3rd: 0.3 to 1.6 | 6 | 11 | 2.8–4.5 | 0.001 |
| 4th: 1.7 to 3.4 | 6 | 35 | 10–122 | <0.0001 |
| 5th: 3.5 to 9.4 | 5 | 33 | 9.2–115 | <0.0001 |
| Hospital bed size | ||||
| 13–25 | 10 | Reference | ||
| 26–50 | 9 | 0.8 | 0.3–2.0 | 0.596 |
| 51–235 | 9 | 1.3 | 0.6–3.0 | 0.530 |
| State | ||||
| Idaho | 17 | Reference | ||
| Utah | 11 | 2.3 | 1.3–4.2 | 0.005 |
*HA-MRSA, heathcare-associated methicillin resistant Staphylococcus aureus; 95% CI, 95% confidence interval; CA-MRSA, community-associated MRSA.
†No. of HA-MRSA cases/10,000 occupied bed-days.
‡No. of CA-MRSA cases/10,000 person-years, based on county population.
Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.